Voyager Therapeutics Company Profile (NASDAQ:VYGR)

About Voyager Therapeutics

Voyager Therapeutics logoVoyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's product pipeline includes programs for Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Its products include VY-AADC01 for Advanced Parkinson's Disease, VY-SOD101 for Monogenic amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich's Ataxia, VY-HTT01 for Huntington's Disease and VY-SMN101 for spinal muscular atrophy (SMA). VY-AADC01 consists of the AAV2 capsid, which has been used in multiple adeno-associated virus (AAV) gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the AADC transgene.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VYGR
  • CUSIP:
Key Metrics:
  • Previous Close: $12.55
  • 50 Day Moving Average: $12.05
  • 200 Day Moving Average: $13.00
  • 52-Week Range: $26,720,000.00 - $8.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.87
  • P/E Growth: 0.00
  • Market Cap: $332.40M
  • Outstanding Shares: 26,720,000
  • Beta: 4.04
Profitability:
  • Net Margins: -195.31%
  • Return on Equity: -20.58%
  • Return on Assets: -15.23%
Debt:
  • Current Ratio: 9.96%
  • Quick Ratio: 9.96%
Additional Links:
Companies Related to Voyager Therapeutics:

Analyst Ratings

Consensus Ratings for Voyager Therapeutics (NASDAQ:VYGR) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $29.25 (135.13% upside)

Analysts' Ratings History for Voyager Therapeutics (NASDAQ:VYGR)
Show:
DateFirmActionRatingPrice TargetDetails
1/20/2017Cowen and CompanyReiterated RatingBuyView Rating Details
1/20/2017WedbushReiterated RatingOutperform$36.00View Rating Details
12/8/2016Chardan CapitalSet Price TargetPositive -> Hold$17.73 -> $11.00View Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$37.00View Rating Details
7/14/2016Stifel NicolausInitiated CoverageBuy -> Buy$33.00View Rating Details
5/20/2016Wells Fargo & CompanyInitiated CoverageOutperformView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Voyager Therapeutics (NASDAQ:VYGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2017        
8/11/2016Q2($0.34)($0.37)ViewListenView Earnings Details
5/12/2016Q1($0.38)$0.29ViewListenView Earnings Details
3/17/2016Q4($0.55)($0.67)$4.94 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Voyager Therapeutics (NASDAQ:VYGR)
Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.81 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.38)($0.38)($0.38)
Q4 20161($0.37)($0.37)($0.37)
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.40)($0.40)($0.40)
Q3 20171($0.42)($0.42)($0.42)
Q4 20171($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Voyager Therapeutics (NASDAQ:VYGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Voyager Therapeutics (NASDAQ:VYGR)
Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 39.95%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Voyager Therapeutics (NASDAQ:VYGR)
DateHeadline
News IconChecking on the Charts for Voyager Therapeutics, Inc. (NASDAQ:VYGR) - BVN (NASDAQ:VYGR)
bvnewsjournal.com - February 17 at 5:08 PM
News IconTrading Watch: Checking in on Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Searcy News (NASDAQ:VYGR)
searcysentinel.com - February 17 at 7:06 AM
finance.yahoo.com logoVoyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS) (NASDAQ:VYGR)
finance.yahoo.com - February 17 at 7:06 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Announces Lead Clinical Candidate Selection for Monogenic Form of ALS - StreetInsider.com (NASDAQ:VYGR)
www.streetinsider.com - February 13 at 9:10 AM
feeds.benzinga.com logoVoyager Therapeutics to Attend Upcoming Investor Conferences (NASDAQ:VYGR)
feeds.benzinga.com - February 2 at 11:40 AM
News IconTrading Corner: Focusing in on Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Gilbert Daily (NASDAQ:VYGR)
gilbertdaily.com - January 30 at 9:56 AM
4-traders.com logoVoyager Therapeutics : Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience (NASDAQ:VYGR)
www.4-traders.com - January 28 at 1:58 AM
News IconFollowing the Numbers on Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - The Tribune (NASDAQ:VYGR)
lakecitytribune.com - January 27 at 3:51 PM
seekingalpha.com logoVoyager Therapeutics: Poised For Gains In 2017 - Seeking Alpha (NASDAQ:VYGR)
seekingalpha.com - January 27 at 3:51 PM
nasdaq.com logoHershey Trust Co Buys JD.com Inc, Barracuda Networks Inc, Global Blood Therapeutics Inc (NASDAQ:VYGR)
www.nasdaq.com - January 25 at 4:27 PM
us.rd.yahoo.com logoVoyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience (NASDAQ:VYGR)
us.rd.yahoo.com - January 25 at 4:27 PM
News IconErratic Volume Stretches This Stock Mid-Session: Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Wall Street Beacon (NASDAQ:VYGR)
wsbeacon.com - January 24 at 8:28 PM
finance.yahoo.com logo7:31 am Voyager Therapeutics announces updates regarding the Phase 1b trial of VY-AADC01 for patients with advanced Parkinson's disease; six-month efficacy results expected mid-2017 (NASDAQ:VYGR)
finance.yahoo.com - January 22 at 8:59 PM
streetinsider.com logoVoyager Therapeutics (VYGR) Offers Update on Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease (NASDAQ:VYGR)
www.streetinsider.com - January 21 at 1:39 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Offers Update on Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease - StreetInsider.com (NASDAQ:VYGR)
www.streetinsider.com - January 20 at 3:36 PM
finance.yahoo.com logoVoyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease (NASDAQ:VYGR)
finance.yahoo.com - January 20 at 3:36 PM
News IconEarnings According to Analysts for Voyager Therapeutics Inc (NASDAQ:VYGR)? - Aiken Advocate (NASDAQ:VYGR)
aikenadvocate.com - January 18 at 1:52 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Appoints Wendy Dixon and Glenn Pierce to Board of Directors - StreetInsider.com (NASDAQ:VYGR)
www.streetinsider.com - January 7 at 6:26 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Appoints Wendy Dixon and Glenn Pierce to Board of Directors (NASDAQ:VYGR)
www.streetinsider.com - January 6 at 6:34 AM
biz.yahoo.com logoVOYAGER THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:VYGR)
biz.yahoo.com - January 6 at 6:34 AM
publicnow.com logoVoyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors (NASDAQ:VYGR)
www.publicnow.com - January 6 at 6:34 AM
finance.yahoo.com logoVoyager Therapeutics (VYGR) Sees Hammer Chart Pattern: Time to Buy? (NASDAQ:VYGR)
finance.yahoo.com - January 4 at 4:26 PM
streetinsider.com logoVoyager Therapeutics (VYGR) Appoints Jane Henderson to CFO (NASDAQ:VYGR)
www.streetinsider.com - January 4 at 7:43 AM
biz.yahoo.com logoVOYAGER THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:VYGR)
us.rd.yahoo.com - January 4 at 7:43 AM
globenewswire.com logoVoyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer - GlobeNewswire (press release) (NASDAQ:VYGR)
globenewswire.com - January 3 at 8:13 AM
publicnow.com logoVoyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer (NASDAQ:VYGR)
www.publicnow.com - January 3 at 8:13 AM
News IconGrowth Story Unfolding for Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Prospect Journal (NASDAQ:VYGR)
prospectjournal.com - December 26 at 7:41 PM
capitalcube.com logoVoyager Therapeutics, Inc. – Value Analysis (NASDAQ:VYGR) : December 23, 2016 (NASDAQ:VYGR)
www.capitalcube.com - December 24 at 1:53 AM
capitalcube.com logoVoyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : December 22, 2016 (NASDAQ:VYGR)
www.capitalcube.com - December 23 at 4:27 AM
bizjournals.com logoThis Cambridge biotech CEO just bought an $8M condo in Millennium Tower (NASDAQ:VYGR)
www.bizjournals.com - December 19 at 3:16 PM
marketwatch.com logoVoyager Therapeutics' stock soars after Parkinson's disease treatment's positive trial results - MarketWatch (NASDAQ:VYGR)
www.marketwatch.com - December 10 at 7:41 PM
finance.yahoo.com logoVoyager Therapeutics to Attend Upcoming Investor Conference (NASDAQ:VYGR)
finance.yahoo.com - December 9 at 4:00 PM
News IconPD arrest made? Voyager rounds up cohorts, strikes operation’s brains via trial (NASDAQ:VYGR)
www.bioworld.com - December 8 at 9:34 PM
investopedia.com logoVoyager Spikes on Parkinson’s Drug Data (VYGR) (NASDAQ:VYGR)
www.investopedia.com - December 8 at 9:34 PM
investopedia.com logoVoyager Therapeutics Parkinson’s Drug Shows Promise (NASDAQ:VYGR)
www.investopedia.com - December 8 at 9:34 PM
seekingalpha.com logoVoyager Therapeutics up 35% after hours on positive results from early-stage Parkinson's study (NASDAQ:VYGR)
seekingalpha.com - December 8 at 4:33 PM
tmcnet.com logoVoyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease (NASDAQ:VYGR)
www.tmcnet.com - December 8 at 4:33 PM
streetinsider.com logoVoyager Therapeutics (VYGR) Announces Clinically Meaningful Interim Phase 1b Trial of VY-AADC01 Data (NASDAQ:VYGR)
www.streetinsider.com - December 8 at 4:33 PM
thestreet.com logoVoyager Therapeutics' Gene Therapy Shows Early, Promising Results (NASDAQ:VYGR)
www.thestreet.com - December 8 at 4:33 PM
insidermonkey.com logoVoyager Therapeutics Inc (VYGR) Has Plenty Of Near Term Catalysts To Watch (NASDAQ:VYGR)
www.insidermonkey.com - December 8 at 4:33 PM
us.rd.yahoo.com logo4:05 pm Voyager Therapeutics announces 'positive' interim results from phase 1b trial of VY-AADC01 for advanced parkinson's disease; on track to report Cohort 3 data mid-2017 and to begin placebo-controlled trial 4Q17 (NASDAQ:VYGR)
us.rd.yahoo.com - December 7 at 9:29 PM
thestreet.com logoVoyager Gene Therapy Shows Early, Promising Motor Function Improvements for Parkinson's Patients (NASDAQ:VYGR)
www.thestreet.com - December 7 at 9:29 PM
finance.yahoo.com logoAn experimental treatment to help Parkinson's patients respond to medication better appears to be working (NASDAQ:VYGR)
finance.yahoo.com - December 7 at 9:29 PM
finance.yahoo.com logoVoyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease (NASDAQ:VYGR)
finance.yahoo.com - December 7 at 9:29 PM
biz.yahoo.com logoVOYAGER THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:VYGR)
biz.yahoo.com - December 7 at 9:29 PM
bizjournals.com logoCambridge gene therapy firm Voyager gets positive results on Parkinson's treatment (NASDAQ:VYGR)
www.bizjournals.com - December 7 at 9:29 PM
capitalcube.com logoETFs with exposure to Voyager Therapeutics, Inc. : December 2, 2016 (NASDAQ:VYGR)
www.capitalcube.com - December 2 at 8:12 PM
capitalcube.com logoVoyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : December 1, 2016 (NASDAQ:VYGR)
www.capitalcube.com - December 1 at 9:22 PM
streetinsider.com logoVoyager (VYGR) Exercises Options to Use REGENXBIO’s (RGNX) NAV Vectors (NASDAQ:VYGR)
www.streetinsider.com - November 29 at 1:12 PM
streetinsider.com logoVoyager (VYGR) Exercises Options to Use REGENXBIO’s (RGNX) NAV Vectors (NASDAQ:VYGR)
www.streetinsider.com - November 29 at 1:12 PM

Social

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Where is Voyager Therapeutics' stock going? Where will Voyager Therapeutics' stock price be in 2017?

6 equities research analysts have issued 12-month price objectives for Voyager Therapeutics' shares. Their predictions range from $11.00 to $37.00. On average, they expect Voyager Therapeutics' share price to reach $29.25 in the next twelve months.

When will Voyager Therapeutics announce their earnings?

Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 15th 2017.

What are analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:

  • Cowen and Company analysts commented, "This morning VYGR released an update from VY-AADC01’s Ph Ib in Parkinson’s." (1/20/2017)

  • According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/18/2017)

Who owns Voyager Therapeutics stock?

Voyager Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.87%), Bain Capital Public Equity Management LLC (5.67%), Eventide Asset Management LLC (1.12%), Deerfield Management Co. (0.88%), State Street Corp (0.62%) and Harbourvest Partners LLC (0.14%).

Who bought Voyager Therapeutics stock? Who is buying Voyager Therapeutics stock?

Voyager Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Harbourvest Partners LLC, Bessemer Group Inc., Russell Investments Group Ltd., Aberdeen Asset Management PLC UK and State Street Corp.

How do I buy Voyager Therapeutics stock?

Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Voyager Therapeutics stock cost?

One share of Voyager Therapeutics stock can currently be purchased for approximately $12.44.

Voyager Therapeutics (NASDAQ:VYGR) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Earnings History Chart

Earnings by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Dividend History Chart

Dividend Payments by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Last Updated on 2/19/2017 by MarketBeat.com Staff